Benefits
What the Q-SYMBIO Trial Tested (Ubiquinone, Not Ubiquinol)
Q-SYMBIO was a 2-year randomized, double-blind trial in 420 people with moderate-to-severe chronic heart failure already on standard therapy. It tested CoQ10 as ubiquinone, the oxidized form, at 100 mg three times daily (300 mg/day). Major adverse cardiovascular events occurred in 15% of the CoQ10 group vs 26% on placebo (HR 0.50, 95% CI 0.32 to 0.80, p=0.003), and all-cause deaths were 21 (10%) vs 39 (18%), p=0.036. Two things matter about that trial. Its product was Myoqinon (Pharma Nord), a ubiquinone preparation that does not contain ubiquinol, so the result belongs to the oxidized form and not to the reduced form sold on this page. And everyone enrolled was a patient with diagnosed heart failure already taking prescribed therapy under medical supervision. Nothing here was tested in healthy people, and a supplement is not a substitute for prescribed treatment.
Absorption vs Ubiquinone (Plasma Levels Only, n=12)
Body must convert ubiquinone (oxidized) to ubiquinol (reduced) for antioxidant function — requires reductase enzymes. Aging, statins, and certain conditions reduce conversion capacity. Ubiquinol skips that conversion step, which is why it is sold at a premium. The evidence cited here is one comparison study in 12 healthy volunteers: 200 mg/day for 4 weeks raised plasma total CoQ10 to 4.3 µg/mL on ubiquinol vs 2.5 µg/mL on ubiquinone (p<0.005). It measured no health outcome and reported no separate result for older adults or statin users. Higher blood levels are not the same as feeling or functioning better.
Statins and CoQ10 Synthesis (Mechanism Only Here)
Statins inhibit HMG-CoA reductase — same pathway that produces CoQ10. May reduce muscle CoQ10 and contribute to statin myalgia. No study cited on this page tested CoQ10 or ubiquinol against muscle symptoms in statin users, and trials in the wider literature have given mixed results. Treat the shared pathway as a reason people try it, not as a demonstrated effect, and never change or stop a statin without talking to the prescriber.
Mitochondrial Function
CoQ10 is critical electron carrier between Complex I/II and Complex III in the mitochondrial electron transport chain. Required for ATP production. Ubiquinol's reduced form participates in both mitochondrial energy production and antioxidant defense against mitochondrial ROS. That is established biochemistry rather than a measured result in healthy people. The only related human measures cited here come from one trial in heart failure patients, where 600 mg/day raised a vigor score and lowered a blood lactate/ATP ratio vs placebo, and a trial in older adults that found no change in oxidative stress markers.
Migraine Research Note (Retired Guideline, Ubiquinone Studies)
The Level C grade often quoted for CoQ10 comes from the 2012 AAN/AHS guideline on episodic migraine, and the AAN retired that guideline in 2015, so it should not be presented as a current recommendation. Those studies used ubiquinone, not ubiquinol, and no migraine study is cited on this page at all. Migraine is a medical condition, and anyone dealing with it should be working with a clinician rather than treating a supplement as the answer.
Better endothelial function (FMD) in adults with high LDL cholesterol
Tested as ubiquinol itself. In 51 adults with LDL 130 to 200 mg/dL, not on statins, 100 or 200 mg/day for 8 weeks raised flow-mediated dilation about 1.3 points, vs a 0.4 fall on placebo. In patients with heart failure with preserved ejection fraction, 600 mg/day for 12 weeks improved a health-status score and BNP vs placebo, not walking distance. In 111 adults over 60, 200 mg/day changed no blood pressure or arterial measure.
Mechanism of action
Mitochondrial Electron Transport
CoQ10 (in oxidized ubiquinone form) accepts electrons from Complex I (NADH dehydrogenase) and Complex II (succinate dehydrogenase), then delivers them to Complex III (cytochrome bc1 complex). Critical for ATP synthesis via oxidative phosphorylation.
Antioxidant in Reduced Form
Ubiquinol (reduced form) donates electrons to neutralize lipid peroxyl radicals — preventing membrane lipid peroxidation. Particularly important in mitochondrial inner membrane. This is established chemistry rather than a measured outcome; in a trial of 111 adults over 60, 200 mg/day for 90 days did not change blood markers of oxidative stress compared with placebo. Recycled by NAD(P)H reductases back to ubiquinol after reducing radicals.
LDL Particle Protection
Ubiquinol concentrates in LDL particles and protects them from oxidative modification. In one trial in adults with high LDL, 200 mg/day for 8 weeks lengthened the lag time before their LDL oxidized in a lab test (a within-group change; circulating oxidized LDL did not change), alongside better flow-mediated dilation vs placebo. That is a lab marker, not a cardiovascular outcome.
Statin Pathway Inhibition
HMG-CoA reductase produces both cholesterol and mevalonate → CoQ10. Statins inhibit this enzyme — reducing CoQ10 synthesis. Long-term statin users may have reduced muscle/tissue CoQ10. Theoretical basis for statin-related myalgia.
Clinical trials
Randomized, double-blind, multicenter trial of CoQ10 as ubiquinone (100 mg three times daily, 300 mg/day) vs placebo, added to standard therapy in 420 patients with moderate-to-severe chronic heart failure (NYHA III-IV), for 2 years (PMID 25282031). Outcomes: major adverse cardiovascular events, mortality.
420 chronic HF patients.
MACE occurred in 15% of the CoQ10 group vs 26% on placebo (HR 0.50, 95% CI 0.32 to 0.80, p=0.003). All-cause deaths were 21 (10%) vs 39 (18%), p=0.036. The trial product was Myoqinon (Pharma Nord), which supplies ubiquinone and does not contain ubiquinol, so this result cannot be read across to the reduced form. Everyone enrolled was a patient on standard prescribed heart failure therapy.
Comparison study of plasma CoQ10 in 12 healthy volunteers taking ubiquinol versus ubiquinone at 200 mg/day for 4 weeks (PMID 27128225). Outcome: plasma total CoQ10 concentration. No clinical or symptom outcome was assessed.
12 healthy volunteers.
Plasma total CoQ10 reached 4.3 µg/mL on ubiquinol vs 2.5 µg/mL on ubiquinone (p<0.005), with no adverse effects. The study describes ubiquinol's absorption as superior, and that is the whole of the finding: 12 healthy people, no older-adult or statin-user subgroup, and no measure of how anyone felt or functioned.